In the latest market close, Aquestive Therapeutics (AQST) reached $3.67, with a +0.55% movement compared to the previous day. The stock exceeded the S&P 500, which registered a gain of 0.52% for the day. Meanwhile, the Dow experienced a rise of 0.12%, and the technology-dominated Nasdaq saw an increase of 0.9%. The specialty pharmaceutical company's stock has climbed by 52.72% in the past month, exceeding the Medical sector's gain of 5.15% and the S&P 500's gain of 3.85%. The investment community will be cl ...

Aquestive Therapeutics (AQST) is expected to report fourth-quarter and full-year 2023 results later this month or early next month. In the last reported quarter, the company beat earnings expectations by 72.73%. Factors to Consider Aquestive earns royalty revenues from its five out-licensed marketed products that it supplies under license deals with partners. Aquestive is the exclusive manufacturer of these licensed products. Its revenues from these products are expected to have increased in the fourth quar ...

股价表现 - Aquestive Therapeutics (AQST) 最新收盘价为$2.65，较前一天下跌了1.67%[1] - 过去一个月，这家专业制药公司的股价上涨了7.37%，表现优于医疗行业的4.52%和标普500指数的3.56%[2] 财务预测 - 分析师预计Aquestive Therapeutics的下一个财报将每股亏损$0.08，同比增长65.22%；预计营收为$11.79百万美元，同比增长10.36%[3] 业务趋势 - 近期分析师对Aquestive Therapeutics的估值变动可能反映了最新的短期业务趋势[4]

The clinical trial data show that epinephrine delivered via orally administered Anaphylm™ (epinephrine) Sublingual Film is comparable to epinephrine delivered via autoinjector or manual intramuscular (IM) injection. Anaphylm candidate, with the potential to be the first and only non-invasive, orally delivered epinephrine product, demonstrates clinical results comparable to autoinjectors (such as EpiPen® and Auvi-Q®) for the emergency treatment of severe allergic reactions, including anaphylaxis. A Phase 3 p ...

Aquestive Therapeutics (AQST) closed at $2.68 in the latest trading session, marking a +1.13% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.96%. Elsewhere, the Dow saw an upswing of 0.4%, while the tech-heavy Nasdaq appreciated by 1.3%. Heading into today, shares of the specialty pharmaceutical company had lost 0.19% over the past month, lagging the Medical sector's gain of 1.18% and the S&P 500's gain of 3.69% in that time. The upcoming earnings release of Aquestiv ...

Aquestive Therapeutics (AQST) ended the recent trading session at $2.68, demonstrating a +1.52% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.06%. Meanwhile, the Dow gained 0.13%, and the Nasdaq, a tech-heavy index, added 0.24%. Shares of the specialty pharmaceutical company have appreciated by 3.13% over the course of the past month, underperforming the Medical sector's gain of 3.52% and the S&P 500's gain of 6.45%. Market participants will be ...

The latest trading session saw Aquestive Therapeutics (AQST) ending at $2.63, denoting a -1.5% adjustment from its last day's close. This change lagged the S&P 500's daily gain of 1.07%. Elsewhere, the Dow gained 0.35%, while the tech-heavy Nasdaq added 1.74%. Heading into today, shares of the specialty pharmaceutical company had gained 18.14% over the past month, outpacing the Medical sector's gain of 4.02% and the S&P 500's gain of 2.93% in that time. The investment community will be paying close attentio ...

公司介绍 - Aquestive Therapeutics, Inc.宣布管理团队将参加Oppenheimer第34届医疗保健生命科学会议[1] - Aquestive是一家制药公司，通过创新科学和传递技术推进药物以改善患者生活[2] - 公司拥有五种在美国和全球市场上由许可方销售的产品，并是这些许可产品的独家制造商[2] - 公司正在推进治疗中枢神经系统疾病的晚期专有产品管线以及早期治疗严重过敏反应的管线[2] - 公司的PharmFilm®和Aquestive标志是Aquestive Therapeutics, Inc.的注册商标[4]

Aquestive Therapeutics (AQST) closed at $2.39 in the latest trading session, marking a +0.84% move from the prior day. The stock's performance was ahead of the S&P 500's daily loss of 0.07%. Elsewhere, the Dow gained 0.16%, while the tech-heavy Nasdaq lost 0.36%. Shares of the specialty pharmaceutical company have appreciated by 18.5% over the course of the past month, outperforming the Medical sector's gain of 1.45% and the S&P 500's gain of 3.05%. The investment community will be closely monitoring the pe ...

The latest trading session saw Aquestive Therapeutics (AQST) ending at $2.50, denoting a -0.4% adjustment from its last day's close. This change lagged the S&P 500's 0.29% gain on the day. On the other hand, the Dow registered a loss of 0.25%, and the technology-centric Nasdaq increased by 0.43%. The the stock of specialty pharmaceutical company has risen by 25.5% in the past month, leading the Medical sector's gain of 2.29% and the S&P 500's gain of 2.08%. The investment community will be closely monitorin ...